Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sunscreen beneficial against skin cancer, including melanoma, AAD says.

This article was originally published in The Tan Sheet

Executive Summary

SUNSCREEN USE BENEFICIAL AGAINST SKIN CANCER, PHOTOAGING, SUNBURN, AAD said in response to a public claim that sun-screens may not help prevent melanoma skin cancer made by Marianne Berwick, PhD, Memorial Sloan-Kettering Cancer Center. Berwick's remarks came at the Association for the Advancement of Science annual meeting in Philadelphia Feb. 17. "We believe it would be irresponsible to recommend that regular use of sunscreen be discontinued," the American Academy of Dermatology said in a Feb. 17 response to Berwick's statements.

You may also be interested in...



High SPF Sunscreens Increase Sun Exposure By 25%, Cancer Study Finds

Individuals who use SPF 30 sunscreens stay in the sun 25% longer than those using SPF 10 sunscreens, according to a study published in the Journal of the National Cancer Institute Aug. 4. The study's SPF 30 sunscreen group spent 1,075 hours sunbathing, compared to the SPF 10 group, which clocked in 852 hours of sun exposure.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel